Pregabalin for the Treatment of Neuropathic Pain: A Systematic Review of Patient-Reported Outcomes

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Oct 30

PMID 39473674

Authors

Zhihui Wang

Iffat Naeem

Tinu Oyenola

Ahmad Raza Khan

Amanda Dennis

Samuel Obamiyi

Emilie Toews

Shilpa Singh

Gebin Zhu

Affiliations

Soon will be listed here.

Abstract

Neuropathic pain (NeP) arises from pathologies of the nervous system, significantly impacting patient functionality and quality of life. Pregabalin is a first-line treatment for NeP, but there has been limited focus on patient-reported outcomes (PROs). This systematic review synthesizes PROs from clinical studies assessing pregabalin's efficacy in treating NeP, with a focus on sleep disturbance, mental health, and health-related quality of life (HRQOL). Following Cochrane Collaboration guidelines, we conducted a systematic search of randomized controlled trials and epidemiological studies reporting PROs associated with pregabalin treatment for NeP. Sixteen studies met the inclusion criteria and were narratively synthesized. The findings indicate that pregabalin significantly improved sleep interference and HRQOL across multiple studies, particularly at doses of 300 mg/day or higher. However, improvements in mental health outcomes, such as anxiety and depression, were inconsistent across studies. No meta-analysis was conducted due to the heterogeneity of outcomes. In conclusion, while pregabalin shows robust efficacy in reducing NeP-related sleep disturbances, its effects on mental health and HRQOL are less consistent. These findings highlight the need for a more holistic approach to NeP treatment, incorporating both clinical outcomes and PROs.

References

Beck A, Ward C, Mendelson M, Mock J, ERBAUGH J . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71. DOI: 10.1001/archpsyc.1961.01710120031004. View

Turk D, Audette J, Levy R, Mackey S, Stanos S . Assessment and treatment of psychosocial comorbidities in patients with neuropathic pain. Mayo Clin Proc. 2010; 85(3 Suppl):S42-50. PMC: 2844010. DOI: 10.4065/mcp.2009.0648. View

ZUNG W . A SELF-RATING DEPRESSION SCALE. Arch Gen Psychiatry. 1965; 12:63-70. DOI: 10.1001/archpsyc.1965.01720310065008. View

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View

Field M, Cox P, Stott E, Melrose H, Offord J, Su T . Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A. 2006; 103(46):17537-42. PMC: 1859964. DOI: 10.1073/pnas.0409066103. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2011; 3(3):e123-30. PMC: 3090117. View

Sabatowski R, Galvez R, Cherry D, Jacquot F, Vincent E, Maisonobe P . Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004; 109(1-2):26-35. DOI: 10.1016/j.pain.2004.01.001. View

Deshpande P, Rajan S, Sudeepthi B, Abdul Nazir C . Patient-reported outcomes: A new era in clinical research. Perspect Clin Res. 2011; 2(4):137-44. PMC: 3227331. DOI: 10.4103/2229-3485.86879. View

Bajwa Z, Ho C . Herpetic neuralgia. Use of combination therapy for pain relief in acute and chronic herpes zoster. Geriatrics. 2002; 56(12):18-24. View

10.

Sheehan D, Raj B . The measurement of disability. Int Clin Psychopharmacol. 1996; 11 Suppl 3:89-95. DOI: 10.1097/00004850-199606003-00015. View

11.

Smith B, Torrance N . Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep. 2012; 16(3):191-8. DOI: 10.1007/s11916-012-0256-0. View

12.

Gureje O, von Korff M, Simon G, Gater R . Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA. 1998; 280(2):147-51. DOI: 10.1001/jama.280.2.147. View

13.

Huffman C, Goldenberg J, Weintraub J, Sanin L, Driscoll J, Yang R . Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients With Postherpetic Neuralgia: A Double-Blind, Enriched Enrollment Randomized Withdrawal, Placebo-Controlled Trial. Clin J Pain. 2016; 33(7):569-578. DOI: 10.1097/AJP.0000000000000445. View

14.

LESSER H, Sharma U, LaMoreaux L, Poole R . Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004; 63(11):2104-10. DOI: 10.1212/01.wnl.0000145767.36287.a1. View

15.

Gore M, Brandenburg N, Dukes E, Hoffman D, Tai K, Stacey B . Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005; 30(4):374-85. DOI: 10.1016/j.jpainsymman.2005.04.009. View

16.

Arezzo J, Rosenstock J, Lamoreaux L, Pauer L . Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008; 8:33. PMC: 2565674. DOI: 10.1186/1471-2377-8-33. View

17.

Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M . Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005; 115(3):254-263. DOI: 10.1016/j.pain.2005.02.032. View

18.

Karimi M, Brazier J . Health, Health-Related Quality of Life, and Quality of Life: What is the Difference?. Pharmacoeconomics. 2016; 34(7):645-9. DOI: 10.1007/s40273-016-0389-9. View

19.

Pande A, Crockatt J, Feltner D, Janney C, Smith W, Weisler R . Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003; 160(3):533-40. DOI: 10.1176/appi.ajp.160.3.533. View

20.

Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T . Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2010; 28(1):109-16. DOI: 10.1111/j.1464-5491.2010.03152.x. View